Online inquiry

IVTScrip™ mRNA-Human ABT1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK10583MR)

This product GTTS-WK10583MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ABT1 protein. This product can be used in Natural killer T (NKT) cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_013375.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 29777
UniProt ID Q9ULW3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ABT1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WK10583MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK15449MR IVTScrip™ mRNA-Human AMER3, (Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMER3
GTTS-WK28110MR IVTScrip™ mRNA-Human ASGR1, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ASGR1
GTTS-WK27668MR IVTScrip™ mRNA-Human ARF6, (Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ARF6
GTTS-WK25054MR IVTScrip™ mRNA-Human ARMC3, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARMC3
GTTS-WK21538MR IVTScrip™ mRNA-Human ANKS3, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ANKS3
GTTS-WK10709MR IVTScrip™ mRNA-Human ADAMTSL3, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADAMTSL3
GTTS-WK5331MR IVTScrip™ mRNA-Human CD34, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD34
GTTS-WK21970MR IVTScrip™ mRNA-Human ARFGAP2, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARFGAP2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW